Immunic Inc. (IMUX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022 6:30 AM EDTInitial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter
Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Expected in the Third Quarter
$88.1 Million in Cash and Cash Equivalents Expected to Fund Immunic Into the Fourth Quarter of 2023
Webcast to be Held Today, August 4, 2022, at 8:00 am ET
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq:... More
